リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study

服部, 誠 名古屋大学

2021.05.26

概要

Introduction
The present study aimed to survey the prevalence of prodromal symptoms of Parkinson’s disease (PD) in Japanese health checkup examinees, for identifying at-risk subjects.

Methods
We conducted a questionnaire survey of annual health checkup examinees without neurological symptoms using the following self-reported questionnaires: Japanese version of the Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT); Self-administered Odor Question (SAOQ); REM Sleep Behavior Disorder Screening Scale (RBDSQ); Beck Depression Inventory-Second Edition (BDI-II); Epworth Sleepiness Scale (ESS); and Physical Activity Scale for the Elderly (PASE). The presence of prodromal symptoms was determined using the 90th percentile threshold of each questionnaire. Subjects≥50 years of age with≥2 core prodromal symptoms (dysautonomia, hyposmia, and RBD), were classified as at risk.

Results
Between March 2017 and March 2018, 4,953 participants sufciently answered the questionnaires. Among 2,726 subjects≥50 years of age, 155 were classifed as at risk. These subjects had worse values of BDI-II (12.0±8.3 vs. 4.4±3.8, p<0.001) and ESS (9.6±5.0 vs. 6.3±3.2, p<0.001), in addition to SCOPA-AUT, SAOQ, and RBDSQ. Male at-risk subjects showed lower values of hemoglobin (14.8±1.3 vs. 15.0±1.1, p=0.032) and low density lipoprotein cholesterol (114.5±30.3 vs. 123.0±28.9, p=0.004) than the examinees reporting no prodromal symptoms.

Conclusion
Approximately 6% of the population aged 50 years or older was at risk for PD. Male at-risk subjects had mild hematological and metabolic changes relevant to PD.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896– 912. https://doi.org/10.1016/S0140-6736(14)61393-3

2. Postuma RB, Aarsland D, Barone P et al (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626. https://doi.org/10.1002/ mds.24996

3. Noyce AJ, Lees AJ, Schrag AE (2016) The prediagnostic phase of Parkinson’s disease. J Neurol Neurosurg Psychiatry 87:871–878. https://doi.org/10.1136/jnnp-2015-311890

4. Jennings D, Siderowf A, Stern M et al (2014) Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology 83:1739–1746. https://doi.org/10.1212/WNL.00000 00000000960

5. Berg D, Godau J, Seppi K et al (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108. https://doi.org/10.1111/j.1468-1331.2012.03798.x

6. Noyce AJ, Bestwick JP, Silveira-Moriyama L et al (2014) PREDICT-PD: identifying risk of Parkinson’s disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry 85:31–37. https://doi.org/10.1136/jnnp-2013-305420

7. Baig F, Lawton M, Rolinski M et al (2015) Delineating nonmotor symptoms in early Parkinson’s disease and frst-degree relatives. Mov Disord 30:1759–1766. https://doi.org/10.1002/mds.26281

8. Gaenslen A, Wurster I, Brockmann K et al (2014) Prodromal features for Parkinson’s disease—baseline data from the TREND study. Eur J Neurol 21:766–772. https://doi.org/10.1111/ ene.12382

9. Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12:622–634. https://doi. org/10.1038/nrneurol.2016.152

10. Ross GW, Abbott RD, Petrovitch H et al (2012) Pre-motor features of Parkinson’s disease: the Honolulu-Asia aging study experience. Park Relat Disord 18:S199–S202. https://doi.org/10.1016/s1353 -8020(11)70062-1

11. Durcan R, Wiblin L, Lawson RA et al (2019) Prevalence and duration of non-motor symptoms in prodromal Parkinson’s disease. Eur J Neurol 26:979–985. https://doi.org/10.1111/ene.13919

12. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184. https://doi.org/10.1136/jnnp.55.3.181

13. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872. https://doi. org/10.1212/01.wnl.0000187889.17253.b1

14. Hagiwara A, Ito N, Sawai K, Kazuma K (2008) Validity and reliability of the Physical Activity Scale for the Elderly (PASE) in Japanese elderly people. Geriatr Gerontol Int 8:143–151. https:// doi.org/10.1111/j.1447-0594.2008.00463.x

15. Matsushima M, Yabe I, Hirotani M et al (2014) Reliability of the Japanese version of the scales for outcomes in Parkinson’s disease-autonomic questionnaire. Clin Neurol Neurosurg 124:182– 184. https://doi.org/10.1016/j.clineuro.2014.07.007

16. Takebayashi H, Tsuzuki K, Oka H et al (2011) Clinical availability of a self-administered odor questionnaire for patients with olfactory disorders. Auris Nasus Larynx 38:65–72. https://doi. org/10.1016/j.anl.2010.05.013

17. Miyamoto T, Miyamoto M, Iwanami M et al (2009) The REM sleep behavior disorder screening questionnaire: validation study of a Japanese version. Sleep Med 10:1151–1154. https://doi. org/10.1016/j.sleep.2009.05.007

18. Beck A, Steer R, Brown G (1996) Beck Depression Inventory Second Edition manual. The Psychological Corporation, San Antonio

19. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545. https://doi. org/10.1093/sleep/14.6.540

20. Schubert CR, Cruickshanks KJ, Fischer ME et al (2012) Olfactory impairment in an adult population: the beaver dam ofspring study. Chem Senses 37:325–334. https://doi.org/10.1093/chemse/bjr102

21. Mahlknecht P, Seppi K, Frauscher B et al (2015) Probable RBD and association with neurodegenerative disease markers: a population-based study. Mov Disord 30:1417–1421. https://doi. org/10.1002/mds.26350

22. Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1611. https://doi.org/10.1002/mds.26431

23. Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244

24. Ministry of Health, Lavor and Welfare, Japan (2012) Summary Results of the National Health and Nutrition Survey Japan. https:// www.mhlw.go.jp/fle/04-Houdouhappyou-10904750-Kenkoukyok u-Gantaisakukenkouzoushinka/0000106403.pdf. Accessed 8 Jan 2020

25. Kawakami N (2016) Report of World Mental Health Japan Survey Second. https://wmhj2.jp/WMHJ2-2016R.pdf. Accessed 8 Jan 2020

26. Chen W, Kang WY, Chen S et al (2015) Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson’s disease. Park Relat Disord 21:610–614. https://doi. org/10.1016/j.parkreldis.2015.03.021

27. Kawasaki I, Baba T, Takeda A, Mori E (2016) Loss of awareness of hyposmia is associated with mild cognitive impairment in Parkinson’s disease. Park Relat Disord 22:74–79. https://doi. org/10.1016/j.parkreldis.2015.11.015

28. Driver JA, Logroscino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson’s disease in advanced age. Neurology 72:432–438. https://doi.org/10.1212/01. wnl.0000341769.50075.bb

29. Zaccai J, McCracken C, Brayne C (2005) A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34:561–566. https://doi.org/10.1093/ageing/af190

30. Fujishiro H, Nakamura S, Sato K, Iseki E (2015) Prodromal dementia with Lewy bodies. Geriatr Gerontol Int 15:817–826. https://doi.org/10.1111/ggi.12466

31. Obeso JA (2019) Editor’s note: Prodromal Parkinson’s disease. Mov Disord 34:664. https://doi.org/10.1002/mds.27707

32. Savica R, Grossardt BR, Carlin JM et al (2009) Anemia or low hemoglobin levels preceding Parkinson disease: a case–control study. Neurology 73:1381–1387. https://doi.org/10.1212/ WNL.0b013e3181bd80c1

33. Hong CT, Huang YH, Liu HY et al (2016) Newly diagnosed anemia increases risk of Parkinson’s disease: a population-based cohort study. Sci Rep 6:1–7. https://doi.org/10.1038/srep29651

34. Rozani V, Gurevich T, Giladi N et al (2018) Higher serum cholesterol and decreased Parkinson’s disease risk: a statin-free cohort study. Mov Disord 33:1298–1305. https://doi.org/10.1002/ mds.27413

35. Sterling NW, Lichtenstein M, Lee EY, et al (2016) Higher plasma LDL-cholesterol is associated with preserved executive and fne motor functions in Parkinson’s disease. Aging Dis 7:237–245. https://doi.org/10.14336/AD.2015.1030

36. Schrag A, Anastasiou Z, Ambler G et al (2019) Predicting diagnosis of Parkinson’s disease: a risk algorithm based on primary care presentations. Mov Disord 34:480–486. https://doi.org/10.1002/ mds.27616

37. Maraki MI, Stefanis L, Yannakoulia M et al (2019) Motor function and the probability of prodromal Parkinson’s disease in older adults. Mov Disord 34:1345–1353. https://doi.org/10.1002/ mds.27792

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る